anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin, which shows new effects, e.g. in particular, prevention of the skin from being rough, dry or eczematous, by compounding a combination of given herbal medicine(s) and edible plant(s). SOLUTION: This preparation for external use for skin contains a combination of the following herbal medicines, namely, Rehmannia glutionosa from Rehmannia glutinosa Liboschitz var. purpurea Makino root, Angelica acutiloba from Angelica acutiloba Kitagawa root, Coix laryma-jobi from Coixlachryma- jobi var. mayuen Stapf L. seed, Glycyrrhiza glabra from Glycyrrhiza uralensis Fischer or Glycyrrhiza glabra Lnnc root or stem, with an essence of Perilla frutescens Britton var. acuta Kudo stems, leaves or seeds extracted with water or alcohol, or their dried powder.
Participants in this condition will receive 3 days of text messages for 4 weeks. Day 1 will consist of psychoeducation about CBT skill, day 2 will be a remainder to use the skill that is framed with toward future benefits from doing so, and day 3 will have a reminder that aims to instill a growth mindset about using the skill.
The invention discloses an anti-tumor polypeptide with double effects and application thereof. The anti-tumor polypeptide with double effects has an amino acid sequence shown in SEQ ID NO. 4. The polypeptide of the invention can specifically target NRP-1 molecules expressed on endothelial cells and tumor cells, improve the permeability of vascular endothelial cells and increase the permeability of tumor tissues, thereby improving the capability of drugs in penetrating vascular barriers and tumor tissues. Meanwhile, the compound can inhibit the proliferation of cancer cells and promote the apoptosis of the cancer cells by blocking a downstream cell signal path regulated by NRP-1. The polypeptide can be used for treating various solid tumors including pancreatic cancer, and can improve the effect of medicaments, particularly monoclonal antibody targeted medicaments, on treating malignant tumors.
BACKGROUND AND PURPOSE: Loss of long-term potentiation (LTP) expression has been associated with a worse disease course in relapsing-remitting multiple sclerosis (RR-MS) and represents a pathophysiological hallmark of progressive multiple sclerosis (PMS). Exercise and physical rehabilitation are the most prominent therapeutic approaches to promote synaptic plasticity. We aimed to explore whether physical exercise is able to improve the expression of LTP-like plasticity in patients with multiple sclerosis (MS).
METHODS: In 46 newly diagnosed RR-MS patients, we explored the impact of preventive exercise on LTP-like plasticity as assessed by intermittent theta-burst stimulation. Patients were divided into sedentary or active, based on physical activity performed during the 6 months prior to diagnosis. Furthermore, in 18 patients with PMS, we evaluated the impact of an 8-week inpatient neurorehabilitation program on clinical scores and LTP-like plasticity explored using paired associative stimulation (PAS). Synaptic plasticity expression was compared in patients and healthy subjects.
RESULTS: Reduced LTP expression was found in RR-MS patients compared with controls. Exercising RR-MS patients showed a greater amount of LTP expression compared with sedentary patients. In PMS patients, LTP expression was reduced compared with controls and increased after 8 weeks of rehabilitation. In this group of patients, LTP magnitude at baseline predicted the improvement in hand dexterity.
CONCLUSIONS: Both preventive exercise and physical rehabilitation may enhance the expression of LTP-like synaptic plasticity in MS, with potential beneficial effects on disability accumulation.
PROBLEM TO BE SOLVED: To obtain a new compound useful as a pharmaceutical composition in order to treat symptoms such as arthritis, e.g. osteoarthritis and rheumatoid arthritis. SOLUTION: This compound is represented by formula I (R<1> is H or a 1-6C alkyl; Y is H or a substituent group on any carbon atom of the phenyl ring independently selected from among fluoro, chloro, trifluoromethyl or the like and capable of supporting an additional bond), preferably ethyl 3-[[4-(4- fluorophenoxy)benzenesulfonyl]-(1-hydroxy-carbamoylcyclobutyl)amino]pr opionate, etc. The compound is preferably obtained by removing, e.g. an R<16> hydroxylamine-protecting group of a compound represented by formula II (R<16> is benzyl) by hydrogenolysis of the benzyl-protecting group in a polar solvent at a temp. of about 20 to about 25 deg.C for about 1 to 5 h using a palladium catalyst on barium sulfate.
PCT No. PCT/US84/01872 Sec. 371 Date Jul. 11, 1985 Sec. 102(e) Date Jul. 11, 1985 PCT Filed Nov. 20, 1984 PCT Pub. No. WO85/02408 PCT Pub. Date Jun. 6, 1985.A method is provided for the controlled introduction of a reagent into a liquid, preferably a reagent peremeable substantially hydrocarbon liquid, which method comprises the steps of: (a) placing as in a geological crude oil reservoir solid polymeric bodies, each body comprising a reagent permeable polymeric matrix containing a substantially water insoluble reagent such as at least one of a wax crystal modifier, demulsifier, scale inhibitor, corrosion inhibitor, biocide, ashless dispersant, antioxidant and mixtures thereof in said liquid (includes both crude and refined hydrocarbon liquids); and, (b) leaching out said reagent from said bodies at a controlled and predetermined rate into said liquid.
###  Patients Not Currently on Tramadol Immediate-Release Products

For patients not currently treated with tramadol immediate-release (IR) products, tramadol hydrochloride ER tablets should be initiated at a dose of 100 mg once daily and titrated up as necessary by 100 mg increments every five days for relief of pain and depending upon tolerability. Tramadol hydrochloride ER tablets should not be administered at a dose exceeding 300 mg per day. 

###  Patients Currently on Tramadol Immediate-Release Products

For patients maintained on tramadol IR products, calculate the 24 hour tramadol IR dose and initiate a total daily dose of tramadol hydrochloride ER tablets rounded down to the next lowest 100 mg increment. The dose may subsequently be individualized according to patient need. Due to limitations in flexibility of dose selection with tramadol hydrochloride ER tablets, some patients maintained on tramadol IR products may not be able to convert tramadol hydrochloride ER tablets. Tramadol hydrochloride ER tablets should not be administered at a dose exceeding 300 mg per day. The concomitant use of tramadol hydrochloride ER tablets with other tramadol products is not recommended (see WARNINGS).
During the fraction 1 insertion, the custom MRI-compatible vaginal cylinder will be placed in the patient, and will contain the 6 degree-of-freedom (DOF) sensor. The electromagnetic navigation system and computer will have been setup in the operating room (OR) prior to the procedure and will be used to actively insert up to 25 catheters into the target. The catheters will be inserted using a custom metallic stylet that has a custom 5-DOF sensor embedded in the tip for tracking its position in real-time. The physician may use ultrasound for assistance in target visualization as well. Catheter deflections will be detected and corrected for in real-time by the radiation oncologist as the catheter is inserted into the patient during the procedure, this will occur when the EM system is in use.
Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
Kidney cancer is the seventh leading cause of cancer in the world, and its incidence is on the rise. Renal cell carcinoma (RCC) is the most common form and is a heterogeneous disease comprising three major subtypes that vary in their histology, clinical course and driver mutations. These subtypes include clear cell RCC, papillary RCC and chromophobe RCC. Molecular analyses of hereditary and sporadic forms of RCC have revealed that this complex and deadly disease is characterized by metabolic pathway alterations in cancer cells that lead to deregulated oxygen and nutrient sensing, as well as impaired tricarboxylic acid cycle activity. These metabolic changes facilitate tumour growth and survival. Specifically, studies of the metabolic features of RCC have led to the discovery of oncometabolites - fumarate and succinate - that can promote tumorigenesis, moonlighting functions of enzymes, and substrate auxotrophy owing to the disruption of pathways that enable the production of arginine and cholesterol. These metabolic alterations within RCC can be exploited to identify new therapeutic targets and interventions, in combination with novel approaches that minimize the systemic toxicity of metabolic inhibitors and reduce the risk of drug resistance owing to metabolic plasticity.
PURPOSE: To impart curls with continuity and soft and smooth cosmetic characteristics to a person's hair treated with silicones by using steam under a specific condition. CONSTITUTION: First, a composition made of silicone derivatives is applied to a person's hair. This treatment with silicones can be given before, during, or after stretching of a bundle of hairs to make a finally requested hair style. Next, the bundle of hairs soaked with the silicones is kept in contact with gas including steam of at least 75 deg.C for a period not exceeding 2 minutes, and next, air is made to flow all through the bundles of hairs speedily at the room temperature, and/or the curled hair is sucked and cooled by air flow. Finally, a mechanical means, which keeps stretching of the bundles of hairs totally treated and set as a requested style, is removed from the hair. In this way, attractive and soft curls can be obtained.
The invention relates to a bag of externally-used medicines for conditioning mammary gland hyperplasia. The bag is characterized by being filled with the following medicinal materials by weight: 10-40g of flos caryophyllata, 10-40g of turmeric roots and tubers, 10-40g of earthworms, 10-40g of towel gourd vegetable sponges, 10-40g of nutgrass galingale rhizomes and 10-80g of red paeony roots. Two bags are made from white cotton cloth by stitching, then the flos caryophyllata, the turmeric roots and tubers, the earthworms, the towel gourd vegetable sponges, the nutgrass galingale rhizomes and the red paeony roots are ground into fine powder together, the two bags are filled with the fine powder equally, the openings of the two bags are sewn up, and a preservative film is attached to one surface of each bag for later use, wherein each bag has a length of 6cm and a width of 5cm. The flos caryophyllata, the turmeric roots and tubers, the earthworms, the towel gourd vegetable sponges, the nutgrass galingale rhizomes and the red paeony roots are combined and compounded to fulfill the functions of soothing the liver, eliminating stagnation, promoting the circulation of qi, relieving pain, promoting the circulation of blood and dredging collaterals. When in use, the two bags filled with medicines are put in interlayers on two sides of a bra flat with the surfaces with no preservative film attached to the breasts closely. To keep the breasts attractive in appearance, the two bags can be both put in the bra. The medicines in the bags need to be changed every seven days.
Proton pump inhibitors (PPIs), such as omeprazole, are the most commonly prescribed drugs. Treatment with PPIs alters gut microbiota composition and reduces the production of reactive oxygen (ROS) and proinflammatory IL-1β, IL-6, and TNF-α cytokines. Here, using the T cell-dependent contact hypersensitivity (CHS) response, an animal model of allergic contact dermatitis (ACD) that affects up to 30% of the population, we demonstrated that a two-week omeprazole treatment suppresses the development of CHS. Omeprazole treatment before CHS induction, reduced inflammatory response in ears measured by ear swelling, ear biopsy weight, MPO activity, and proinflammatory cytokine production. These changes were associated with reduced frequency of TCRαβ+ CD4+ IL-17A+ and TCRαβ+ CD8+ IL-17A+ T cells and increased frequency of TCRαβ+ CD4+ CD25+ FoxP3+ Treg, and TCRαβ+ CD4+ IL-10+ Tr1 cells in peripheral lymphoid organs. Omeprazole treatment decreased the production of ROS, TNF-α, and IL-6, which supported Th17 cell induction, and increased the frequency of Clostridium cluster XIVab and Lactobacillus, implicated in Treg cell induction. The fecal microbiota transplantation (FMT) experiment confirmed the role of omeprazole-induced changes in gut microbiota profile in CHS suppression. Our data suggests that omeprazole ameliorates inflammatory response mediated by T-cells.
ELIPSE-I represents a single-blind randomized controlled parallel-group clinical trial. In ELIPSE-I, 148 children, matched for sex, 6-12 years of age with a BMI \>97 centile based on national growth charts will be included. Children will be recruited at the children's university hospital and randomly (1:1) assigned to a control and intervention group. All participants receive treatment-as-usual (TAU), parents of participants in the intervention group additionally receive a smartphone application (lifestyle app) for 20 weeks. The app aims to promote healthy behavior through cognitive-behavioral impact factors (i.e., psychoeducation, goal setting), that are applied by a psychologist via structured feedback. Single-blinded assessments will be conducted at baseline, following the intervention period of 20 weeks, and at 6-month follow-up after the end of the intervention. The primary endpoint is reduction of the TEI/TEE ratio in children with obesity. Secondary endpoints in ELIPSE-I include lowering the severity of obesity, cardiometabolic risk factor improvement, reduction in chronic low-level inflammatory biomarkers, and improved children's quality of life. A further endpoint is acceptance and usability of the app.
After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
An apparatus providing a fluid for treating a surface comprises a spray head 29 for applying the fluid to the surface, a fluid delivery means for delivering the fluid to the spray head and a catchment tray 11 for collecting the fluid after it has been applied to the surface. A fluid return line 20 removes the fluid from the catchment tray and a pump 22 creates a vacuum in the fluid return line. The apparatus also includes a releaseable coupling 12 which has two engagable parts (13, 14, Fig. 2) and a plurality of channels, one channel is connected to the fluid delivery means and another channel is connected to the fluid return line when the parts are engaged. Each channel comprises a valve which opens when the engagable parts are engaged to allow fluid to flow through the coupling and is closed when the engagable parts are disengaged to prevent fluid flow. A pressure monitor 23 measures the pressure in the fluid return line, wherein the measured pressure is compared to a plurality of pre-set pressure values to determine the correct functioning of the apparatus. Suitably, the apparatus is used to disinfect wounds using aqueous ozone.
For many years, gamma-irradiation in air was a common method for the terminal sterilization of ultrahigh molecular weight polyethylene (UHMWPE) materials used for joint replacement. A serendipitous byproduct of sterilization with gamma-irradiation was polymer crosslinking that tended to improve the wear performance of the polyethylene. During the 1990s, however, the orthopaedic community became aware that gamma-irradiation created free radicals within polyethylene, rendering the material susceptible to oxidative degradation. In view of this potentially deleterious effect, terminal sterilization methods using chemical surface treatments were developed to avoid free radical formation. To induce polyethylene crosslinking without residual free radicals, manufacturers also developed methods to crosslink the polyethylene followed by heat treatments to eliminate free radicals. These crosslinked materials were introduce during the latter part of the 1990s and clinical outcome studies among hip replacement patients have demonstrated substantially reduced wear at early follow-up intervals based on radiographic measurements. However, the long-term performance of crosslinked polyethylene is unknown and some investigators have expressed concerns related to in vivo degradation. Additionally, some crosslinked UHMWPE components have shown high levels of oxidation and chain scission after removal from patients and storage in air. Among these implants, it is unknown whether the oxidation and chain scission occurred during implantation or after the polyethylene was removed from the patient.

This study will characterize the material properties of polyethylene liners retrieved from hip replacement patients. The study population will include crosslinked and conventional UHMWPE liners that were terminally sterilized without the use of radiation. To quantify the potential effects of different storage methods, liners that were vacuum packed and frozen after retrieval and others that were stored at room temperature with access to ambient light and air following explantation will be included in the study population. Analysis techniques will include Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimeter (DSC) and crosslink density measurements. Crosslink density measurements will be evaluated as a function of distance away from the articular surface and the rim of the implant. Gel and hydroperoxide contents will also be evaluated. The goal of the analysis is to better understand the changes in polyethylene material properties that occur in vivo and ex vivo.
In the adult placebo-controlled studies, an analysis of episodes of cognition and attention disturbances was performed for patients on benzodiazepines. One patient receiving prazepam concomitantly with GATTEX 0.05 mg/kg once daily experienced a dramatic deterioration in mental status progressing to coma during the first week of GATTEX therapy. The patient was admitted to the ICU and the prazepam blood concentration was >300 mcg/L. GATTEX and prazepam were discontinued, and coma resolved 5 days later.

Monitor patients receiving concomitant oral drugs requiring titration or with a narrow therapeutic index, for adverse reactions due to potential increased absorption of the concomitant drug. The concomitant drug may require a reduction in dosage [see Drug Interactions (7.1)].
This study was designed to dissect the function of plasmacytoma variant translocation 1 (PVT1) in hippocampal neuron injury in epilepsy and its possible molecular basis. Status epilepticus (SE) mouse model was built and primary hippocampal neurons were isolated. qRT-PCR and Western blot were applied to quantify the levels of related genes and proteins. Cell proliferation and apoptosis were examined by CCK-8, EdU, and flow cytometry assays. Inflammatory factors were detected using ELISA analysis. Dual-luciferase reporter and RIP assays were carried out to validate the relationship between miR-206-3p and PVT1 or CAMK4. PVT1 and CAMK4 were increased, and miR-206-3p was downregulated in the hippocampus and hippocampal neurons of SE mice. Knockdown of PVT1 or CAMK4 abated SE-induced proliferation inhibition, apoptosis, and inflammation in hippocampal neurons. Mechanistically, PVT1 could sponge miR-206-3p to upregulate the expression of CAMK4 in hippocampal neurons. Moreover, downregulation of miR-206-3p reversed the inhibitory effects of PVT1 knockdown on SE-induced apoptosis and inflammation in hippocampal neurons. Similarly, overexpression of CAMK4 abolished miR-206-3p-evoked arrest of apoptosis and inflammation in hippocampal neurons under SE condition. Collectively, PVT1 contributed to SE-induced apoptosis and inflammation in hippocampal neurons by modulating the miR-206-3p/CAMK4 axis, offering a novel insight into the prevention of epilepsy.
An improved method for the treatment of melanoma and skin diseases which utilizes a zinc chloride fixative mixture is provided. The active ingredients of the fixative mixture include zinc chloride (a deeply penetrating, tissue killing histologic preservative), and the anti-cancer plant alkaloids sanguinarine and chelerythrine. Zinc chloride allows the surgeon to perform a complete conventional surgical excision around and below a melanomatous tumor through painless, bloodless dead tissue, and because the microscopic structures are fixed in place by the zinc chloride, the excised tissue can be examined by a pathologist to confirm complete excision and clearance of the melanoma. Although zinc chloride fixative paste has been shown to be an effective treatment for human skin cancer and melanoma, this treatment has been overlooked by the medical community. The paste is difficult to maintain and complicated to apply to the affected skin. This invention allows the active ingredients of zinc chloride fixative paste to be effectively administered to the skin by providing single-use dose specific storage, application, dressing, and administration systems needed to facilitate the use of topical zinc chloride mixtures and/or zinc chloride pastes in the treatment of melanoma and other skin diseases. Enhanced zinc chloride mixture formulations are described.
This is a prospective randomized study. Patients had uncontrolled glaucoma on maximum tolerated medical therapy including acetazolamide tablets were enrolled in this clinical trial and were randomized to tight flap technique group (group A) and loose flap technique group(group B). Randomization assigned 40 patients to group A and 40 patients to do group B. A total of 80 patients were enrolled in the Study between 2012 and 2014.

During trabeculectomy, Trabecular meshwork and scleral lamellae were excised made an opening with the kelly scleral punch 1.0 mm 3-5 bites. At 12 o'clock 10/0 nylon monofilament stitch was used to close the apex of triangular scleral flap tightly and two releasable stitches were used at the sides of triangular scleral flap in group A. Fig-1 At 12 o'clock 10/0 nylon monofilament stitch was used to secure the edges of the flap at the apex of and two-four releasable stitches were used at the sides of triangular scleral flap in group B. The intraocular pressure and bleb morphology were followed for one year after surgery.
Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
We will use the intraoperatively collected etCO2 levels to classify patients as either 'with hypocapnia' or 'without hypercapnia', using the cutoff of 35 mmHg. A patient is considered 'hypocapnic' if the etCO2 was \< 35 mm Hg at any point during surgery, from start of the study till end of the study, and classified as 'without hypocapnia' otherwise. In case of a missing value immediately before extubation, we will use the values as reported in the last hour of surgery.
Participants with HCC will receive E7386, twice daily (BID) for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386, BID in combination with lenvatinib 8 mg (participants with body weight of \< 60 kg) or 12 mg (participants with body weight \>=60 kg) capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.